257 related articles for article (PubMed ID: 32508844)
1. CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy.
Joly-Amado A; Hunter J; Quadri Z; Zamudio F; Rocha-Rangel PV; Chan D; Kesarwani A; Nash K; Lee DC; Morgan D; Gordon MN; Selenica MB
Front Immunol; 2020; 11():997. PubMed ID: 32508844
[TBL] [Abstract][Full Text] [Related]
2. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model.
Ghosh S; Wu MD; Shaftel SS; Kyrkanides S; LaFerla FM; Olschowka JA; O'Banion MK
J Neurosci; 2013 Mar; 33(11):5053-64. PubMed ID: 23486975
[TBL] [Abstract][Full Text] [Related]
3. Tau exhibits unique seeding properties in globular glial tauopathy.
Chung DC; Carlomagno Y; Cook CN; Jansen-West K; Daughrity L; Lewis-Tuffin LJ; Castanedes-Casey M; DeTure M; Dickson DW; Petrucelli L
Acta Neuropathol Commun; 2019 Mar; 7(1):36. PubMed ID: 30845985
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice.
Zaheer S; Thangavel R; Wu Y; Khan MM; Kempuraj D; Zaheer A
Neurochem Res; 2013 Jan; 38(1):218-25. PubMed ID: 23086473
[TBL] [Abstract][Full Text] [Related]
5. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease.
Hopp SC; Lin Y; Oakley D; Roe AD; DeVos SL; Hanlon D; Hyman BT
J Neuroinflammation; 2018 Sep; 15(1):269. PubMed ID: 30227881
[TBL] [Abstract][Full Text] [Related]
6. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.
DeVos SL; Corjuc BT; Commins C; Dujardin S; Bannon RN; Corjuc D; Moore BD; Bennett RE; Jorfi M; Gonzales JA; Dooley PM; Roe AD; Pitstick R; Irimia D; Frosch MP; Carlson GA; Hyman BT
Brain; 2018 Jul; 141(7):2194-2212. PubMed ID: 29733334
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition.
Yamamoto M; Horiba M; Buescher JL; Huang D; Gendelman HE; Ransohoff RM; Ikezu T
Am J Pathol; 2005 May; 166(5):1475-85. PubMed ID: 15855647
[TBL] [Abstract][Full Text] [Related]
9. Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease.
Li HQ; Ip SP; Yuan QJ; Zheng GQ; Tsim KKW; Dong TTX; Lin G; Han Y; Liu Y; Xian YF; Lin ZX
Brain Behav Immun; 2019 Nov; 82():264-278. PubMed ID: 31476414
[TBL] [Abstract][Full Text] [Related]
10. Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis.
Terron HM; Parikh SJ; Abdul-Hay SO; Sahara T; Kang D; Dickson DW; Saftig P; LaFerla FM; Lane S; Leissring MA
Alzheimers Res Ther; 2024 Apr; 16(1):70. PubMed ID: 38575959
[TBL] [Abstract][Full Text] [Related]
11. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.
Nash KR; Lee DC; Hunt JB; Morganti JM; Selenica ML; Moran P; Reid P; Brownlow M; Guang-Yu Yang C; Savalia M; Gemma C; Bickford PC; Gordon MN; Morgan D
Neurobiol Aging; 2013 Jun; 34(6):1540-8. PubMed ID: 23332170
[TBL] [Abstract][Full Text] [Related]
12. Cellular and pathological heterogeneity of primary tauopathies.
Chung DC; Roemer S; Petrucelli L; Dickson DW
Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
[TBL] [Abstract][Full Text] [Related]
13. Chemogenetic attenuation of neuronal activity in the entorhinal cortex reduces Aβ and tau pathology in the hippocampus.
Rodriguez GA; Barrett GM; Duff KE; Hussaini SA
PLoS Biol; 2020 Aug; 18(8):e3000851. PubMed ID: 32822389
[TBL] [Abstract][Full Text] [Related]
14. IFN-γ promotes τ phosphorylation without affecting mature tangles.
Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
FASEB J; 2015 Oct; 29(10):4384-98. PubMed ID: 26156074
[TBL] [Abstract][Full Text] [Related]
15. Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model.
Seino Y; Kawarabayashi T; Wakasaya Y; Watanabe M; Takamura A; Yamamoto-Watanabe Y; Kurata T; Abe K; Ikeda M; Westaway D; Murakami T; Hyslop PS; Matsubara E; Shoji M
J Neurosci Res; 2010 Dec; 88(16):3547-54. PubMed ID: 20936700
[TBL] [Abstract][Full Text] [Related]
16. Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Clippinger AK; D'Alton S; Lin WL; Gendron TF; Howard J; Borchelt DR; Cannon A; Carlomagno Y; Chakrabarty P; Cook C; Golde TE; Levites Y; Ranum L; Schultheis PJ; Xu G; Petrucelli L; Sahara N; Dickson DW; Giasson B; Lewis J
Acta Neuropathol; 2013 Jul; 126(1):39-50. PubMed ID: 23666556
[TBL] [Abstract][Full Text] [Related]
17. Glial contributions to neurodegeneration in tauopathies.
Leyns CEG; Holtzman DM
Mol Neurodegener; 2017 Jun; 12(1):50. PubMed ID: 28662669
[TBL] [Abstract][Full Text] [Related]
18. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
19. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
[TBL] [Abstract][Full Text] [Related]
20. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
